SCHEMBL20053971

SCHEMBL20053971

Cc1cc(-c2ccnc(N/C(C=N)=C/NC3CCOCC3)n2)ccc1CNC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 3/20 0.44
▸ AAK1 Q2M2I8 4/20 0.42
▸ BTK Q06187 14/20 0.41
▸ JAK2 O60674 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ HRH2 P25021 1/20 0.38
▸ CDK7 P50613 1/20 0.38
▸ CD69 Q07108 1/20 0.38
▸ MAP3K19 Q56UN5 1/20 0.38
▸ CDKL2 Q92772 1/20 0.38
▸ RIOK1 Q9BRS2 1/20 0.38
▸ RIOK2 Q9BVS4 1/20 0.38
▸ BMP2K Q9NSY1 1/20 0.38
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ MAPK3 P27361 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20053900 0.91 BTK (0.43) AAK1BTKJAK2CYP3A4HRH2
SCHEMBL20053917 0.88 AAK1 (0.47) AAK1BTKJAK2CYP3A4HRH2
SCHEMBL20053961 0.87 MAPK1 (0.40) MAPK1BTKJAK2CDK7CCNA2
SCHEMBL20461151 0.84 BTK (0.61) MAPK1AAK1BTKJAK2CYP3A4
SCHEMBL20053927 0.83 AAK1 (0.45) AAK1BTK
SCHEMBL20054038 0.79 BTK (0.46) AAK1BTKJAK2CYP3A4HRH2
SCHEMBL20054045 0.78 AAK1 (0.47) AAK1BTK
SCHEMBL20053902 0.78 AAK1 (0.46) AAK1BTKJAK2CYP3A4HRH2
SCHEMBL20461227 0.76 BTK (0.58) AAK1BTKJAK2CYP3A4HRH2
SCHEMBL20461157 0.76 BTK (0.36) MAPK1AAK1BTKJAK2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3357921-A2 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY Sunesis Pharmaceuticals, Inc. (US) 2018-08-08 — — EP disclosed
EP-3080103-B1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY BIOGEN MA INC (US) 2018-04-18 — — EP disclosed
Send feedback